Grants for Small businesses - Federal

This grant provides funding for researchers to develop advanced human cell-based systems that better mimic the complex functions of the nervous system, aiming to improve the understanding and treatment of brain and spinal cord disorders.

This program provides funding for researchers and innovators to develop advanced technologies for rapidly identifying and sequencing complex protein-based biothreats, enhancing national security and defense capabilities.

This funding opportunity supports research using advanced cellular models to investigate HIV interactions with tissues related to diabetes, digestive, and kidney diseases, particularly focusing on HIV persistence, latency, and related health issues.

This funding opportunity supports collaborative research efforts to improve the prevention, treatment, and understanding of cancers associated with HIV, involving various specialized teams and clinical trials accessible to diverse populations.

This funding opportunity supports researchers analyzing existing genomic data related to dental, oral, and craniofacial health to address research gaps and improve health outcomes.

This funding opportunity provides financial support for projects that enhance the domestic processing, manufacturing, and recycling of critical battery materials to strengthen U.S. supply chains and reduce reliance on foreign sources.

This funding opportunity supports early postdoctoral fellows from diverse backgrounds in cancer research, providing them with mentorship and training to advance their careers in addressing health disparities and enhancing the cancer research workforce.

This funding opportunity provides financial support for engineering studies to develop infrastructure for transporting captured carbon dioxide, targeting private companies, governments, non-profits, and educational institutions committed to reducing greenhouse gas emissions and promoting community benefits.

This funding opportunity provides financial support to U.S.-based small businesses that have previously received Phase I awards to further develop and commercialize innovative research in agriculture, food systems, and environmental sustainability.

This grant provides funding to organizations that will deliver training and support to improve early childhood education and development practices for children from birth to age five in Head Start and Early Head Start programs.

The U.S. Department of State, Bureau of Oceans and International Environmental and Scientific Affairs (OES) announces an open competition (see eligibility information in Funding Announcement), under the Toxic Chemicals earmark to reduce and mitigate environmental contamination and human exposures to lead by supporting capacity-building efforts for environmentally sound end-of-life management of lead-acid batteries (LABs) and used lead-acid batteries (ULABs) in Africa. This program aims to reduce lead pollution as well as promote and advance environmentally sustainable consumption and production at international, national, and subnational levels.

This funding opportunity supports small businesses that have completed a Phase II SBIR or STTR award in advancing clinical trials and research projects for medical products, particularly those requiring federal regulatory approval, while encouraging partnerships with investors to ensure commercial viability.

This funding opportunity provides financial support to organizations that will help improve diabetes prevention and management for underserved populations by offering expertise, training, and resources to enhance health equity.

This funding opportunity provides financial support to institutions with active Clinical and Translational Science Awards to develop innovative programs that address critical challenges in clinical research and improve the efficiency of translating scientific discoveries into practical applications.

This funding opportunity supports U.S.-based small businesses in developing and manufacturing therapeutic extracellular vesicles for regenerative medicine applications, focusing on tissue and organ repair.

This funding opportunity provides financial support for innovative research projects aimed at understanding the neurological and mental health effects of chronic illnesses linked to infections, such as Long COVID and chronic fatigue syndrome, encouraging studies that explore their underlying mechanisms.

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Small Business Concerns (SBCs) holding Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be nationally underrepresented in health-related research or in the SBIR and STTR programs. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

This funding opportunity supports community hospitals and oncology practices in expanding access to cancer research and clinical trials for diverse populations, focusing on participant recruitment and insights into local care disparities.

The FY24 DMDRP CTRA mechanism supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data relevant to DMD to support the proposed research project.This mechanism is intended to support established projects that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed.Early-Career Partnering PI Option: The FY24 DMDRP encourages applications that include meaningful and productive collaborations between investigators. In an effort to promote enhanced research capacity within the DMD field, the FY24 CTRA includes an option for an Early-Career Partnering Principal Investigator (PI). The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Early-Career PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.The FY24 DMDRP CTRA offers two funding levels (refer to Section II.D.5 Funding Restrictions). Only one funding level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of the research appropriate for each funding level:Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $650,000.Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $1.35M.Additionally, both funding levels will support an Early-Career Partnering PI Option at the same maximum direct costs and periods of performance, respectively.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Both pilot clinical trials and clinical research are permitted under this mechanism.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.All investigators applying to FY24 DMDRP funding opportunities and conducting clinical research are encouraged to consult the Strategies to Promote Diversity in Muscular Dystrophy Research Participation developed by the MDCC.

This funding opportunity supports researchers exploring innovative strategies to achieve long-lasting HIV remission at the start of antiretroviral therapy, focusing on basic and preclinical studies rather than clinical trials.